Cingulate, Inc. operates as a clinical stage biopharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages 18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Follow-Up Questions
What is Cingulate Inc (CING)'s P/E Ratio?
The P/E ratio of Cingulate Inc is N/A
Who is the CEO of Cingulate Inc?
Dr. Shane Schaffer is the Chairman of the Board of Cingulate Inc, joining the firm since 2012.
What is the price performance of CING stock?
The current price of CING is 3.54, it has increased 0.72% in the last trading day.
What are the primary business themes or industries for Cingulate Inc?
Cingulate Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Cingulate Inc market cap?
Cingulate Inc's current market cap is $19.8
Is Cingulate Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Cingulate Inc, including 2 strong buy, 7 buy, 1 hold, 0 sell, and 2 strong sell
